10-K: Nuo Therapeutics Reports 126% Revenue Growth, Secures $1.6M Loan

Sentiment:

Annual Report 30 March 2026 5:38 PM

Nuo Therapeutics, a medical device company, announced significant revenue growth in 2025 driven by its Aurix product and a new distribution agreement with Smith+Nephew, alongside securing new debt financing, despite ongoing net losses and a going concern warning.

Capital raiseThe company explicitly states a need to raise substantial additional funds to continue as a going concern and support operations for the next 12 months.A shelf registration statement on Form S-3, declared effective May 12, 2025, enables the company to offer and sell up to $15 million in common stock from time to time.The company closed a private placement in July 2025, selling 527,612 shares of common stock for proceeds of $791,418.A Loan and Security Agreement was entered into on January 21, 2026, providing for up to $1.6 million in loans, with $1.0 million initially funded and a potential $600,000 second funding by September 30, 2026.The Loan Agreement involves the issuance of various warrants (Commitment, Origination Initial, Capital Initial, Origination Second, Capital Second, Prepayment, and Interest Warrants) to lenders, which could lead to future equity dilution upon exercise.

Worse than expectedThe company reported a net loss of $2.5 million in 2025, an increase from the $2.3 million loss in 2024, indicating continued unprofitability.The gross margin declined from 78% in 2024 to 67% in 2025, primarily due to sales of centrifuge devices to Smith+Nephew at near-zero gross margins.The company explicitly states "substantial doubt about our ability to continue as a going concern" and that current resources are "insufficient to support our operations for the next 12 months."Operating expenses increased significantly by over $1.2 million, outpacing the growth in gross profit, contributing to the larger net loss.

Summary

Total revenues for the year ended December 31, 2025, reached approximately $3.3 million, a substantial increase from $1.4 million in 2024.
Product revenues alone grew by approximately 126% to $3.1 million in 2025, primarily due to an expanding customer base and initial sales under the Smith+Nephew private label distribution agreement.
A distribution agreement with Smith+Nephew, effective March 31, 2025, includes an upfront distribution fee of $1.5 million, of which $225,000 was recognized as revenue in 2025.
The company incurred a net loss of approximately $2.5 million in 2025, slightly higher than the $2.3 million net loss in 2024.
Gross profit increased to approximately $2.2 million in 2025 from $1.1 million in 2024, though the gross margin declined to 67% from 78% due to near-zero margins on centrifuge devices sold to Smith+Nephew.
Operating expenses rose to approximately $4.7 million in 2025 from $3.5 million in 2024, driven by increased professional fees, third-party commission expenses, and compensation costs.
As of December 31, 2025, cash and cash equivalents were approximately $0.5 million, with an accumulated deficit of $34.8 million and a stockholders' deficit of $1.0 million.
The company secured a Loan and Security Agreement on January 21, 2026, providing for up to $1.6 million in loans, with $1.0 million funded initially and $600,000 potentially funded by September 30, 2026.
The loans bear interest at 10% (initial) or 12% (if second funding occurs), payable in warrants, and are secured by all company assets, including intellectual property.
A material weakness in internal control over financial reporting was identified due to insufficient accounting and financial reporting resources, with remediation efforts ongoing.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with low sentiment due to the explicit 'going concern' warning, persistent net losses, and declining gross margin, despite notable revenue growth and new financing. The company's financial stability remains highly uncertain.

Positives

Product revenues increased significantly by approximately 126% to $3.1 million in 2025 from $1.4 million in 2024, indicating growing market adoption for the Aurix System.
The distribution agreement with Smith+Nephew, a global medical technology company, provides an upfront distribution fee of $1.5 million and potential additional milestone fees of $750,000, enhancing revenue streams and market reach.
CMS national coverage determination (NCD) for autologous PRP for chronic non-healing diabetic wounds provides economically viable reimbursement, with 2026 rates of $2,108 per treatment in hospital outpatient settings and $1,064 in private offices.
The company successfully secured new debt financing of up to $1.6 million in January 2026, with $1.0 million already funded, providing crucial capital for operations.
The company has expanded its contractual relationships to over 200 third-party entity and individual representatives as of December 31, 2025.

Negatives

The company continues to incur recurring net losses, with approximately $2.5 million in 2025 and $2.3 million in 2024.
A substantial doubt exists about the company's ability to continue as a going concern, as current resources and projected revenue are deemed insufficient to support operations for the next 12 months.
The gross margin declined to approximately 67% in 2025 from 78% in 2024, primarily due to selling centrifuge devices to Smith+Nephew at a near-zero gross margin.
Operating expenses increased by approximately $1.2 million in 2025, driven by higher professional fees, third-party commissions, and compensation costs.
The company has a limited revenue base, relying on a single product (Aurix) for market adoption, which presents concentration risk.
A material weakness in internal control over financial reporting was identified due to insufficient accounting and financial reporting resources, which could undermine timely, accurate, and reliable financial reporting.
The company relies on a single supplier (Pfizer) for a critical reagent (bovine thrombin) used in the Aurix product, posing supply chain risk and potential for price increases.

Risks

Limited revenue base and sources of working capital, with a history of losses and no current profitability.
Ability to continue as a going concern is in substantial doubt, requiring additional financing which may not be obtainable on satisfactory terms or at all.
Dilutive impact of raising additional equity or debt on existing stockholders' ownership interests.
Inability to timely and accurately report financial results or prevent fraud due to material weakness in internal control over financial reporting.
Acceptance of the Aurix product by the medical community and patients is crucial for commercial success.
Ability to obtain adequate reimbursement from third-party payors, including potential future regulations or cost-control initiatives that could restrict product pricing.
Reliance on several single-source suppliers, particularly Pfizer for bovine thrombin, which could lead to supply interruptions or increased costs.
Inability to protect intellectual property (trademarks, trade secrets) from misappropriation or deter others from developing similar technology.
Competition from pharmaceutical, biopharmaceutical, and medical device companies, including Smith+Nephew's private label product, which directly competes with Aurix.
Inability to attract and retain key personnel, including executive officers, given the small team size of 10 full-time employees.
Malpractice or product liability claims could be asserted against the company, with current insurance coverage potentially inadequate.
Smith+Nephew may not establish a sufficient market for its Private Label product, or may terminate the distribution agreement, adversely affecting revenues.
The existence of a private label alternative (Smith+Nephew's product) may limit potential customers and sales for the company's own Aurix product.
Information systems failures or data breaches could disrupt operations, lead to loss of confidential information, and result in legal or regulatory claims.
Data privacy security failures or breaches could expose the company to regulatory and other liability.
The retail trading market for common stock on OTCQB is limited, subject to wider spreads, increased volatility, and penny stock rules, which may discourage broker-dealers.
Notification, negotiation, and participation rights granted to Smith+Nephew may impact the company's ability to license Aurix, enter into a business combination, or sell equity securities on favorable terms.

Future Outlook

The company anticipates continued revenue growth for its Aurix product by expanding relationships with clinical providers and treatment facilities through distributor and sales agent arrangements. Revenues under the Smith+Nephew distribution agreement are expected to increase modestly over the next 12 months as Smith+Nephew establishes full commercial sales. However, the company's current resources and projected revenue are insufficient to support operations for the next 12 months, necessitating substantial additional funding to avoid delaying or reducing its business plan and pursuing commercial payor insurance reimbursement.

Management Comments

"Our current commercial focus is to continue engaging and establishing relationships with providers treating chronic non-healing wounds to demonstrate the clinical benefits we believe result from the use of Aurix in the treatment of complex wounds."
"Increasing physician awareness of the differentiating attributes of Aurix will be key to establishing a base of product revenues upon which to grow."
"We anticipate developing these relationships with clinical providers and treatment facilities primarily by establishing a variety of distributor and sales agent arrangements throughout the United States and internationally."
"We believe that Smith+Nephew will need time to establish full commercial sales of its Private Label product via its direct and indirect sales efforts. As a result, our revenues under the Distribution Agreement may increase modestly during the next 12 months."
"Our continuing losses and limited cash resources raise substantial doubt about our ability to continue as a going concern, and we need to raise substantial additional funds in order to continue to conduct our business."

Industry Context

StockSavvy.ai notes that Nuo Therapeutics operates in the advanced wound care market, a significant global sector estimated at $10.8 billion in 2021, with North America accounting for approximately $4.15 billion in 2020. The market is driven by an aging population and increasing prevalence of diabetes, leading to a growing patient population with chronic, non-healing wounds. The company's focus on autologous platelet-rich plasma (PRP) therapy aligns with a broader trend towards cell-based regenerative medicine. The favorable CMS National Coverage Determination for PRP products is a critical industry development, providing a clear reimbursement pathway that is essential for commercial viability in the U.S. healthcare system. However, the market is highly competitive, with established players offering advanced dressings, devices, and biologics, and Nuo's reliance on a single product and limited resources presents a challenge against larger, more diversified competitors.

Comparison to Industry Standards

Nuo Therapeutics' Aurix System competes in the advanced wound care market, which includes advanced wound care dressings, wound care devices, and wound care biologics. Leading companies in this broader market include 3M, MoInlycke, and ConvaTec.
In the biologic products segment, competitors offering tissue-based products include companies such as MiMedx, Organogenesis, and Integra Life Sciences, alongside numerous smaller companies.
The company's 2025 revenue of $3.3 million is significantly smaller compared to these established industry leaders, highlighting its niche position and the substantial market share held by larger, more diversified players.
The gross margin of 67% in 2025, while healthy, saw a decline from 78% in 2024, partly due to strategic pricing with Smith+Nephew, which may be a necessary trade-off for broader market penetration through a major distributor.
The company's reliance on a single product and limited R&D investment (no significant costs in 2024 or 2025) contrasts with the continuous innovation and product pipeline development typically seen in larger medical technology and biopharmaceutical companies.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Audit Committee Financial Expert Designation	The Board has determined that Mr. C. Eric Winzer is independent and is an audit committee financial expert as defined by Item 407(d)(5) of Regulation S-K.	NA	Enhances financial oversight and compliance with regulatory requirements for financial reporting.
Insider Trading Policy Adoption	The company adopted an Insider Trading Policy, effective October 27, 2025, to promote compliance with federal and state securities laws and prohibit certain transactions while in possession of material non-public information.	October 27, 2025	Strengthens internal controls against insider trading and enhances corporate integrity, though two directors had late Section 16(a) filings in 2025.
Code of Conduct and Ethics Adoption	The Board adopted a Code of Conduct and Ethics applicable to all directors, officers, and employees in accordance with Item 406 of Regulation S-K.	NA	Establishes clear ethical guidelines and promotes a culture of compliance and integrity within the company.

Related Party Transactions

Scott M. Pittman, a director and principal stockholder, loaned $200,000 in the initial funding of the January 2026 Loan Agreement and committed to loaning an additional $210,000 in a potential second funding.
Paul Anthony Jacobs, a principal stockholder, loaned $300,000 in the initial funding of the January 2026 Loan Agreement.
Warrants were issued to Scott M. Pittman and Paul Anthony Jacobs as part of the Loan Agreement, including Commitment Warrants, Origination Initial Warrants, Capital Initial Warrants, and potentially Origination Second, Capital Second, Prepayment, and Interest Warrants.
In the July 2025 private placement, Scott M. Pittman invested $5,919, Charles E. Sheedy (a principal stockholder) invested $200,000, and Paul Anthony Jacobs invested $300,000.
In the May 2024 private placement, Scott M. Pittman invested $101,250, Peter A. Clausen (CSO/COO) invested $11,250, and Charles E. Sheedy invested $75,000.
In the September 2024 private placement, Charles E. Sheedy invested $93,750.
David E. Jorden (CEO/CFO) and Peter A. Clausen (CSO/COO) had their annual base salaries increased effective October 1, 2025, to $325,000 and $290,000, respectively. Their employment agreements include severance payments under certain circumstances.

Stakeholder Impact

**Shareholders**: Face significant dilution risk from ongoing equity and warrant issuances to fund operations. The 'going concern' doubt poses a substantial risk to investment value. The limited liquidity and penny stock status of the common stock on OTCQB also impact tradability and price volatility.
**Employees**: The company's limited number of employees (10 full-time) and reliance on key executives (Jorden and Clausen) means their retention is critical. The ongoing financial challenges could impact job security and future compensation opportunities, despite recent salary increases for executives.
**Customers (Healthcare Providers)**: Benefit from the continued availability of the Aurix System and favorable CMS reimbursement. The distribution agreement with Smith+Nephew could expand access to the product, but the existence of a private label alternative might create confusion or shift purchasing patterns.
**Suppliers**: The company's reliance on single-source suppliers, particularly Pfizer for bovine thrombin, creates a concentration risk for the company, but also provides a stable revenue stream for those suppliers. Any financial instability of Nuo could impact its ability to pay suppliers.
**Creditors**: The new Loan and Security Agreement provides a secured interest in all company assets, including intellectual property, offering some protection. However, the 'going concern' doubt indicates elevated risk for all creditors.

Next Steps

Continue engaging and establishing relationships with providers treating chronic non-healing wounds to demonstrate clinical benefits of Aurix.
Expand distributor and sales agent arrangements throughout the United States and internationally.
Broaden commercial customer relationships with wound care providers in private office settings.
Engage with hospitals and hospital systems regarding expanded POS 22 usage and ensure appropriate administration of reimbursement mechanisms.
Smith+Nephew will work to establish full commercial sales of its Private Label product.
The company will incur expenses under the Distribution Agreement to comply with its provisions and associated packaging, shipping, and related costs.
Assess the need for hiring additional internal accounting and third-party financial reporting resources to remediate material weaknesses in internal controls.
Implement further measures to improve internal control over financial reporting, including validation and testing over sustained financial reporting cycles.
Potentially pursue a Second Funding of $600,000 under the Loan Agreement by September 30, 2026, if requested and subject to closing conditions.
Repay principal on the secured notes in equal quarterly installments commencing March 31, 2027, until the maturity date of December 31, 2028.
File all required state income tax returns within the next 12 months (as of March 30, 2026).

Key Dates

Date	Description
1998	Company organized as Informatix Holdings, Inc.
1999	Autologous Wound Therapy, Inc. merged with Informatix Holdings, Inc., changing the name to Autologous Wound Therapy, Inc.
2000	Autologous Wound Therapy, Inc. changed its name to Cytomedix, Inc.
2001	Cytomedix filed for bankruptcy.
2002	Cytomedix emerged from bankruptcy.
2003	David E. Jorden joined Morgan Stanley's Private Wealth Management group.
September 2007	Cytomedix received Section 510(k) clearance from the FDA for the AutoloGel System (now Aurix System).
October 2008	David E. Jorden joined the Board of Directors.
September 2008	Peter A. Clausen originally joined the company.
January 30, 2009	C. Eric Winzer joined the Board of Directors.
June 2009	C. Eric Winzer became Principal Accounting Officer, SVP of Finance, and CFO for OpGen Inc.
2010	Cytomedix acquired the Angel Whole Blood Separation System.
2011	Paul D. Mintz, MD, served as Director, Division of Hematology Clinical Review, Office of Blood Research and Review, Center for Biologics Evaluation and Research of the U.S. Food and Drug Administration.
2012	Cytomedix acquired Aldagen, Inc.
2012	Medicare National Coverage Determination (NCD) from CMS reversed a twenty-year old non-coverage decision for autologous blood derived products used in wound care.
June 2013	David E. Jorden became CEO for Nanospectra Biosciences, Inc.
2014	Cytomedix changed its name to Nuo Therapeutics, Inc.
March 30, 2014	Peter A. Clausen was appointed Chief Scientific Officer.
May 2015	David E. Jorden became Acting Chief Financial Officer.
May 2015	C. Eric Winzer became CFO at Immunomic Therapeutics, Inc.
January 8, 2016	David E. Jorden became Acting Chief Executive Officer.
Early 2016	Paul D. Mintz, MD, joined Verax Biomedical, Inc.
2016	Company filed for and emerged from bankruptcy under Chapter 11.
May 5, 2016	Scott M. Pittman joined the Board of Directors.
July 1, 2016	David E. Jorden became Chief Executive and Financial Officer.
July 2016	Board of Directors approved the 2016 Omnibus Incentive Plan.
November 2016	Stockholders approved the 2016 Omnibus Incentive Plan.
April 7, 2017	Paul D. Mintz, MD, joined the Board of Directors.
May 1, 2019	Company furloughed remaining employees and ceased standard operational activities.
May 8, 2019	Formal public request for reconsideration of NCD submitted to CMS.
December 31, 2019	Peter A. Clausen's tenure as Chief Scientific Officer ended.
March 2020	Peter A. Clausen joined Arthrex Inc. as senior product manager.
April 2021	CMS issued a favorable National Coverage Determination (NCD) for autologous PRP products.
October 2021	Company restarted business activities following favorable NCD.
January 1, 2022	Peter A. Clausen became Chief Scientific and Operating Officer.
March 4, 2022	Equity awards fully vested for Mr. Jorden and Dr. Clausen in settlement of accrued compensation liabilities.
May 2022	Commercially available Aurix product first became available for demonstration and evaluation purposes.
May 9, 2022	Employment agreements with David Jorden and Peter Clausen became effective.
August 22, 2022	Shares of common stock resumed trading on the OTCQB.
August 2022	Company entered into a Common Stock and Warrant Purchase Agreement with Pacific Medical, Inc.
January 1, 2024	Pacific Medical's 2024 Financing Participation warrant was issued with an exercise price of $0.56 per share.
May 2024	Company sold 867,833 shares of common stock in a private placement for $650,875.
June 7, 2024	MaloneBailey, LLP became the independent registered public accounting firm.
June 27, 2024	Pacific Medical exercised 270,000 warrants for $151,200.
July 2024	Compensation, Nominating and Governance Committee resumed granting non-cash compensation to non-executive directors.
September 2024	Company sold 1,132,167 shares of common stock in a private placement for $849,125.
November 2024	CMS issued its final Physician Fee Schedule for calendar 2025, establishing a national average payment of $890 for Aurix in POS 11.
January 1, 2025	Aurix System became economically viable within the physician office care setting due to CMS final PFS.
March 31, 2025	Company entered into a Distribution Agreement with Smith & Nephew, Inc.
April 1, 2025	Dr. Clausen's annual salary was reestablished at $225,000.
April 2025	C. Eric Winzer retired from Immunomic Therapeutics, Inc.
May 12, 2025	SEC declared the company's shelf registration statement on Form S-3 effective, allowing for up to $15 million in equity offerings.
May 14, 2025	Amendment No. 1 to the Distribution Agreement with Smith+Nephew was entered into, providing for an interim sales agency arrangement.
July 2025	Company sold 527,612 shares of common stock in a private placement for $791,418.
July 30, 2025	Closing of the 2025 Private Placement occurred.
August 2025	Compensation, Nominating and Governance Committee resumed awarding cash compensation to non-executive directors.
October 1, 2025	Mr. Jorden's and Dr. Clausen's annual base salaries were increased to $325,000 and $290,000, respectively.
October 2025	First commercial sales under the Smith+Nephew distribution agreement commenced.
December 30, 2025	Amendment No. 2 to the Distribution Agreement was entered into, adding certain expansion kits.
December 31, 2025	Interim sales agency arrangement with Smith+Nephew terminated.
December 31, 2025	Company had 10 full-time employees.
December 31, 2025	Prefunding of $500,000 in secured notes by two lenders occurred.
January 1, 2026	Amendment No. 2 to the Distribution Agreement became effective.
January 15, 2026	Final determination date for the 200,000 sales incentive warrant, after which it will be considered cancelled and forfeited if performance goals are not met.
January 21, 2026	Company entered into a Loan and Security Agreement with four lenders.
January 23, 2026	Closing of the Initial Funding of $1.0 million under the Loan Agreement occurred, and warrants were issued to lenders.
March 15, 2026	Number of shares outstanding of common stock was 48,289,296.
March 26, 2026	Number of shares outstanding of common stock was 48,289,296.
March 30, 2026	Date of signing of the Annual Report on Form 10-K.
September 30, 2026	Potential date for the Second Funding of $600,000 under the Loan Agreement.
September 2026	Expiration of Smith+Nephew's 18-month notification and first negotiation rights for licensing or business combination.
December 31, 2026	Notes under the Loan Agreement are interest-only through this date; voluntary prepayment without fee possible on or after this date.
March 31, 2027	Principal repayment on the Notes begins in equal quarterly installments.
December 31, 2027	Prepayment fee of 1.5% applies if Notes are prepaid before this date; no fee on or after this date.
December 31, 2028	Maturity date of the Initial Note and any Second Note under the Loan Agreement.
January 23, 2031	Expiration date of warrants issued under the Loan Agreement.

Recommendation

strong sell

The company explicitly states "substantial doubt about our ability to continue as a going concern" and that its current resources are insufficient for the next 12 months. While revenue growth is positive, it's overshadowed by persistent net losses, a declining gross margin, and significant operating expense increases. The reliance on a single product, intense competition, and material weaknesses in internal controls further compound the risk. Despite recent financing, the long-term viability is highly questionable, making the stock a strong sell for seasoned investors.

Keywords

Nuo Therapeutics, Aurix System, chronic wound care, platelet rich plasma, PRP, medical device, SEC filing, 10-K, Smith+Nephew, distribution agreement, reimbursement, CMS, diabetic foot ulcers, going concern, debt financing, private placement, internal controls, biotechnology, healthcare, OTC Markets

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.